Some studies suggest that specific hormonal contraceptive methods [particularly depot medroxyprogesterone acetate (DMPA)] may increase women's HIV acquisition risk. We updated a systematic review to incorporate recent epidemiological data.
We searched for articles published between 15 January 2014 and 15 January 2016 and hand-searched reference lists. We identified longitudinal studies comparing users of a specific hormonal contraceptive method against either nonusers of hormonal contraception or users of another specific hormonal contraceptive method. We added newly identified studies to those in the previous review, assessed study quality, created forest plots to display results, and conducted a meta-analysis for data on DMPA versus non-use of hormonal contraception.
We identified 10 new reports of which five were considered ‘unlikely to inform the primary question’. We focus on the other five reports, along with nine from the previous review, which were considered ‘informative but with important limitations’. The preponderance of data for oral contraceptive pills, injectable norethisterone enanthate, and levonorgestrel implants do not suggest an association with HIV acquisition, though data for implants are limited. The new, higher quality studies on DMPA (or nondisaggregated injectables), which had mixed results in terms of statistical significance, had hazard ratios between 1.2 and 1.7, consistent with our meta-analytic estimate for all higher quality studies of hazard ratio 1.4.
Although confounding in these observational data cannot be excluded, new information increases concerns about DMPA and HIV acquisition risk in women. If the association is causal, the magnitude of effect is likely hazard ratio 1.5 or less. Data for other hormonal contraceptive methods, including norethisterone enanthate, are largely reassuring.
Supplemental Digital Content is available in the text
aGuttmacher Institute, New York, New York
bDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
cDivision of Reproductive Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA
dCentre of Primary Academic Care, University of Aberdeen, United Kingdom
eDepartment of Family Medicine, Boston University School of Medicine/Boston Medical Center, Boston, Massachusetts, USA
fDepartment of Obstetrics and Gynecology, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
gDepartment of Reproductive Health and Research, World Health Organization (WHO), Geneva, Switzerland
hDepartment of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, USA.
Correspondence to Chelsea B. Polis, PhD, Guttmacher Institute, 125 Maiden Lane, 7th Floor, New York, NY 10038, USA. E-mail: firstname.lastname@example.org
Received 1 June, 2016
Revised 26 July, 2016
Accepted 3 August, 2016
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).
This is an open-access article distributed under the terms of the Creative Commons Attribution Licence 3.0 IGO, which permits unrestricted use, distribution, and reproduction in any medium, provided the work is properly cited. http://creativecommons.org/licenses/by/4.0